The accompanying
notes are an integral part of the condensed financial statements.
The accompanying
notes are an integral part of the condensed financial statements.
The accompanying
notes are an integral part of the condensed financial statements.
The accompanying
notes are an integral part of the condensed financial statements.
Notes to
Condensed Financial Statements
NOTES TO CONDENSED FINANCIAL STATEMENTS (unaudited)
NOTE 1 -
BASIS OF PRESENTATION
The accompanying
unaudited financial statements were prepared in accordance with instructions for Form 10-Q and, therefore, do not include information
or footnotes necessary for a complete presentation of financial condition, results of operations, and cash flows in conformity
with U.S. Generally Accepted Accounting Principles US GAAP. All adjustments, consisting of normal recurring accruals, which, in
the opinion of management, are necessary for fair presentation of the financial statements, have been included. The results of
operations for the period ended December 31, 2014, are not necessarily indicative of the results which may be expected for the
entire fiscal year or for any other period. For further information, refer to the financial statements and footnotes thereto for
the year ended December 31, 2013 included in PureSpectrum Inc.'s Form 10-K.
Certain
prior year amounts have been reclassified to conform to the 2014 presentation.
NOTE 2 –
RECENT ACCOUNTING PRONOUNCEMENTS
The Company’s
management does not believe that recent codified pronouncements by the Financial Accounting Standards Board FASB will have a material
impact on the Company’s current or future financial statements.
NOTE 3 -
SUMMARY OF ORGANIZATION
PureSpectrum,
Inc. (the “Company”), formerly International Medical Staffing, Inc., is a Delaware corporation incorporated on March
21, 2007. The Company is in the business of developing, marketing, licensing, and contract manufacturing of lighting technology
for use in residential, commercial, and industrial applications worldwide.
The Company
is authorized to issue 950 million shares, consisting of (a) 900 million shares of common stock, par value $0.0001 per share and
(b) 50 million shares of preferred stock, par value $0.0001 per share, which may be issuable in one or more series. Each common
share is entitled to one vote and shareholders have no preemptive or conversion rights. As of December 31, 2014, and December 31,
2013, there were 636,368,278 and 351,691,363 common shares issued and outstanding, respectively. The Company's Board of Directors
may, without further action by the shareholders, direct the issuance of preferred stock for any proper corporate purpose with preferences,
voting powers, conversion rights, qualifications, special or relative rights and privileges which could adversely affect the voting
power or other rights of shareholders of common stock. As of December 31, 2011, and December 31, 2010, there were 2,300,000 and
2,300,000 shares of the Company's preferred stock issued or outstanding, respectively. Each Series B preferred share entitles the
holder thereof to five hundred (500) votes per share and may vote on any action requiring any class of shares to vote.
NOTE 4 –
GOING CONCERN
The accompanying
financial statements have been prepared in conformity with US GAAP, which contemplate continuation of the Company as a going concern
and the realization of assets and liquidation of liabilities in the normal course of business. The Company has incurred net losses
from operations of $758,647 for the year ended December 31, 2014. In addition, at December 31, 2014, the Company has an accumulated
deficit of $219,615,127 and negative working capital of $3,098,868.
These
factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.
The
Company recorded its first revenues in October 2009 and is no longer a development stage company. The Company has not yet generated
sufficient working capital to support its operations. The Company’s ability to continue as a going concern is dependent,
among other things, on its ability to minimize costs, enter into revenue generating contracts and obtain additional revenues to
eventually attain a profitable level of operations.
The
Company has been engaged in developing, marketing, licensing, and contract manufacturing of fluorescent lighting technology for
use in residential, commercial, and industrial applications worldwide. There can be no assurance that the Company will be successful
in the commercialization of the fluorescent lighting technology that will generate sufficient revenues to sustain the operations
of the Company.
Management
plans to obtain additional capital investments to enable the Company to continue operations and decrease revenues in 2014. There
is no assurance that management will be able to successfully generate revenue and/or reduce expenses sufficient to attain profitability,
or continue to attract the capital necessary to support the business.
NOTE
5 - NET LOSS PER SHARE
Basic net loss per share is computed by dividing net loss attributable to commons shareholders by the weighted
average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss
per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the
treasury stock method. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common
share equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, convertible
preferred stock, stock options and warrants are considered to be common stock equivalents and are only included in the calculation
of diluted net loss per share when their effect is dilutive.
|
|
Year ended December 31,
|
|
|
|
2014
|
|
|
2013
|
|
Actual
|
|
|
|
|
|
|
Numerator:
|
|
|
|
|
|
|
Net loss attributable to common stockholders
|
|
$
|
(758,647
|
)
|
|
$
|
(5,109,113
|
)
|
|
|
|
|
|
|
|
|
|
Denominator:
|
|
|
|
|
|
|
|
|
Weighted average common shares
|
|
|
533,588,558
|
|
|
|
247,008,376
|
|
|
|
|
|
|
|
|
|
|
Basic net loss per common share
|
|
$
|
(0.00
|
)
|
|
$
|
(0.02
|
)
|
|
|
|
|
|
|
|
|
|
Historical outstanding anti-dilutive securities not included in diluted net loss per share calculation
|
|
|
|
|
|
|
|
|
Convertible debt
|
|
|
2,834,363,938
|
|
|
|
78,202,568
|
|
Common stock options
|
|
|
50,757,468
|
|
|
|
40,288,738
|
|
Common stock warrants
|
|
|
82,800,000
|
|
|
|
52,300,000
|
|
|
|
|
2,967,921,406
|
|
|
|
170,791,306
|
|
NOTE 6 – NOTES PAYABLE
Notes payable consist of the following:
|
|
December 31,
|
|
|
|
2014
|
|
|
2013
|
|
Note payable, unsecured, to shareholder at 5% interest, payable upon demand
|
|
$
|
61,650
|
|
|
$
|
61,650
|
|
Note payable, unsecured, to officer at 5% interest, payable upon demand
|
|
|
–
|
|
|
|
–
|
|
|
|
|
61,650
|
|
|
|
61,650
|
|
Less current portion
|
|
|
61,650
|
|
|
|
61,650
|
|
Long term portion
|
|
$
|
–
|
|
|
$
|
–
|
|
NOTE 7
– OPTIONS AND WARRANTS
Options
and warrants generally vest immediately upon grant. The Company has historically issued warrants related to raising capital. As
of December 31, 2014, the Company has 50,757,468 options outstanding and exercisable and 82,800,000 warrants outstanding and exercisable.
Information
about stock options and warrants outstanding at December 31, 2014 and December 31, 2013 is summarized below:
|
|
Shares
|
|
|
Weighted Average Exercise Price Per Share
|
|
|
Weighted Average Remaining Contractual Life
|
|
|
|
Warrants
|
|
|
Stock Options
|
|
|
Warrants
|
|
|
Stock Options
|
|
|
Warrants
|
|
|
Stock Options
|
|
Outstanding at December 31, 2013
|
|
|
82,800,000
|
|
|
|
50,757,468
|
|
|
|
0.750
|
|
|
|
0.060
|
|
|
|
3.2
|
|
|
|
3.2
|
|
Granted
|
|
|
–
|
|
|
|
–
|
|
|
|
–
|
|
|
|
–
|
|
|
|
–
|
|
|
|
|
|
Exercised
|
|
|
–
|
|
|
|
–
|
|
|
|
–
|
|
|
|
–
|
|
|
|
–
|
|
|
|
|
|
Cancelled or Expired
|
|
|
–
|
|
|
|
–
|
|
|
|
–
|
|
|
|
–
|
|
|
|
–
|
|
|
|
|
|
Outstanding at December 31, 2014
|
|
|
82,800,000
|
|
|
|
50,757,468
|
|
|
|
0.750
|
|
|
|
0.060
|
|
|
|
3.2
|
|
|
|
3.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable at December 31, 2014
|
|
|
82,800,000
|
|
|
|
50,757,468
|
|
|
|
0.750
|
|
|
|
0.060
|
|
|
|
3.2
|
|
|
|
3.2
|
|
NOTE 8
- OPERATING LEASES AND OTHER COMMITMENTS AND CONTINGENCIES
Rental of
office space and data processing equipment under operating leases were approximately $6,000 and $52,216 for the six months ended
December 31, 2014 and 2013, respectively.
NOTE 9
- RELATED PARTY TRANSACTIONS
Not applicable
NOTE 10
- SUBSEQUENT EVENTS
On July
29, 2014 the Company issued a Convertible Promissory Note in the amount of $5,000. The Note is due January 29, 2015.
On July
29, 2014 the Company created a wholly owned subsidiary, Pure Spectrum Oil Inc., a Nevada corporation.